| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
|
Waller, Cornelius F.
|
|
2015
|
16 |
2 |
p. 92-99
8 p.
|
artikel
|
| 2 |
Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer
|
Li, Sen
|
|
2015
|
16 |
2 |
p. 86-91
6 p.
|
artikel
|
| 3 |
Comparative Effectiveness of First-Line Platinum-Based Chemotherapy Regimens for Advanced Lung Squamous Cell Carcinoma
|
Liao, Bin-Chi
|
|
2015
|
16 |
2 |
p. 137-143
7 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2015
|
16 |
2 |
p. A6-
1 p.
|
artikel
|
| 5 |
Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non–Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis
|
Zhang, Yaxiong
|
|
2015
|
16 |
2 |
p. 144-151.e1
1367 p.
|
artikel
|
| 6 |
Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non–Small-Cell Lung Cancer After Definitive Radiotherapy
|
Wang, Hongmei
|
|
2015
|
16 |
2 |
p. 128-136
9 p.
|
artikel
|
| 7 |
Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient
|
Bugés, Cristina
|
|
2015
|
16 |
2 |
p. e1-e3
nvt p.
|
artikel
|
| 8 |
Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review
|
Zhao, Ning
|
|
2015
|
16 |
2 |
p. e5-e9
nvt p.
|
artikel
|
| 9 |
Lung Cancer Hormesis in High Impact States Where Nuclear Testing Occurred
|
Lehrer, Steven
|
|
2015
|
16 |
2 |
p. 152-155
4 p.
|
artikel
|
| 10 |
Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study
|
Yu, Shaomin
|
|
2015
|
16 |
2 |
p. 121-127
7 p.
|
artikel
|
| 11 |
Radical-Intent Hypofractionated Radiotherapy for Locally Advanced Non–Small-Cell Lung Cancer: A Systematic Review of the Literature
|
Kaster, Tyler S.
|
|
2015
|
16 |
2 |
p. 71-79
9 p.
|
artikel
|
| 12 |
ROS1 Immunohistochemistry Among Major Genotypes of Non–Small-Cell Lung Cancer
|
Boyle, Theresa A.
|
|
2015
|
16 |
2 |
p. 106-111
6 p.
|
artikel
|
| 13 |
Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501
|
Gervais, Radj
|
|
2015
|
16 |
2 |
p. 100-105
6 p.
|
artikel
|
| 14 |
Standard Treatment Option in Stage III Non–Small-Cell Lung Cancer: Case Against Trimodal Therapy and Consolidation Drug Therapy
|
Jeremić, Branislav
|
|
2015
|
16 |
2 |
p. 80-85
6 p.
|
artikel
|
| 15 |
Stereotactic Radiotherapy in the Treatment of Primary Bronchial Carcinoid Tumor
|
Colaco, Rovel J.
|
|
2015
|
16 |
2 |
p. e11-e14
nvt p.
|
artikel
|
| 16 |
Table of Contents
|
|
|
2015
|
16 |
2 |
p. A10-A12
nvt p.
|
artikel
|
| 17 |
Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non–Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation
|
Swanick, Cameron W.
|
|
2015
|
16 |
2 |
p. 156-163
8 p.
|
artikel
|
| 18 |
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment
|
Langer, Corey J.
|
|
2015
|
16 |
2 |
p. 112-120
9 p.
|
artikel
|
Tijdschrift beschrijving